PDCD1 and non-small cell lung carcinoma: This upregulation of PD-1/PD-L1 pathway provides a strong scientific rationale for the use of PD-1/PD-L1 inhibitors following CRT, as supported by the efficacy of consolidation durvalumab and pembrolizumab in unresectable stage III non-small cell lung cancer (19, 20).